Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company") is pleased to announce that, in accordance with its equity incentive plan, it has issued a total of 3,000,000 restricted share units (RSUs) and 2,500,000 stock options to directors, officers, and consultants of the Company.
The RSUs and options were granted as part of DiagnaMed's ongoing efforts to align the interests of its leadership and key partners with those of shareholders, and to reward contributions to the Company's continued growth and development.
The 2,500,000 stock options have an exercise price of $0.05 per share and are exercisable for a period of three (3) years from the date of grant. All RSUs and options are subject to the terms and conditions of the Company's equity incentive plan and applicable regulatory approvals.
These grants reflect the Board's confidence in the strategic direction of the Company, particularly as it advances its natural hydrogen projects in Ontario alongside its collaborative partners, INRS and QIMC. This initiative underscores DiagnaMed's commitment to driving innovation and growth in the natural hydrogen sector in Ontario.
The Company continues to advance its hydrogen development initiatives and enhance operational execution, strategically scaling its platform to capitalize on growth opportunities within the expanding natural hydrogen sector. This includes the ongoing deployment of the QIMC and INRS teams in Northern Ontario.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a Canadian technology innovator specializing in advanced hydrogen extraction technologies designed to support the rapidly growing natural hydrogen industry. Focused on commercial scalability, DiagnaMed aims to deliver cost-effective, sustainable, and efficient hydrogen solutions critical for global energy security and decarbonization. Visit DiagnaMed.com.
For more information, please contact:
John Karagiannidis, President and CEO
DiagnaMed Holdings Corp.
Tel: 514-726-7058
Email: info@diagnamed.com
Website: www.diagnamed.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement
Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as "will", "may", "expect", "could", "can", "estimate", "anticipate", "intend", "believe", "projected", "aims", and "continue" or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the Three and Six Months Ended March 31, 2025 ("MD&A"), dated May 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259573
SOURCE: DiagnaMed Holdings Corp.
